Skin and Connective Tissue Diseases

445 trials 165 recruiting

Filter these 445 trials by phase, country and sponsor.

Open in Search →

A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended

2022-500332-11-00 systemic sclerosis 4 2022-11-25
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose ranging Study to Assess the Efficacy and Safety of CDX 0159 in Patients with Ch… Ended

2024-516988-87-00 Chronic Inducible Urticaria 4 2022-11-09
Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and … Ended

2024-514788-24-00 Chronic stable plaque psoriasis 5 2022-09-20
Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis. Ended

2024-512791-36-00 Treatment of moderate-to-severe Atopic dermatitis 4 2022-08-24
Study investigating the safety and efficacy of a new iodine formulation called DLQ03 in a wound-healing model in patients with atopic eczema Ended

2022-500647-21-00 Atopic dermatitis (Eczema) 7 2022-08-04
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of RO7303509 in Patients with Systemic Sclero… Ended

2022-502981-26-00 Systemic Sclerosis 3 2022-06-27
Adjusted brodalumab dose compared with standard brodalumab dose in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight… Ended

2023-509668-11-00 Moderate-to-severe plaque psoriasis and a body weight ≥ 6 2022-06-15
The WILLOW study with enpatoran in SLE and CLE (SCLE and/or DLE) Ended

2024-510872-18-00 Systemic lupus erythematosus (SLE) and cutaneous lupus 4 2022-05-09
A phase I/II, multicenter, randomized, double-blind, placebo within-patient controlled, first-in-human (FIH) Proof of Concept (PoC) study to… Ended

2023-507743-11-00 Netherton syndrome (NS) 7 2022-02-18
Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended

2024-514907-32-00 non-metastatic soft tissue sarcoma 3 2022-01-21
A Multicenter trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects with Moderate-to-Severe Atopic … Ended

2024-514405-65-00 Atopic Dermatitis 4 2021-11-22
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Su… Ended

2024-512142-42-00 Psoriatic Arthritis 5 2021-10-05
Study to investigate the efficacy and safety of allo-APZ2-CVU on wound healing of therapy-resistant chronic venous ulcer (CVU) Ended

2023-510162-27-00 Chronic venous ulcers (CVU) 4 2021-08-18
An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects… Ended

2024-515534-32-00 Subjects with nummular eczema 4 2021-03-15
ADMSC-fib safety and efficacy in patients with chronico wounds Ended

2024-518789-29-00 chronic wounds 4 2021-03-15
A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Su… Ended

2024-520057-20-00 Plaque Psoriasis 4 2021-03-09
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Tildrakizumab in Anti-TNF Experien… Ended

2023-507415-35-00 Psoriatic Arthritis 5 2021-01-15
Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC) Ended

2024-517678-12-00 METASTATIC SOFT-TISSUE SARCOMAS AFTER FAILURE ON AT LE 9 2021-01-14
Mogamulizumab Every 4 Week dosing in Participants with R/R CTCL Ended

2024-515921-27-00 Mycosis fungoides/Sezary syndrome recurrent 4 2021-01-13
A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyositis (DM) Ended

2023-508293-28-00 Dermatomyositis 5 2020-02-20
Medical-scientific research into a new own skin graft product (EHSG-KF) Ended

2024-512188-29-00 Adults and adolescents with partial deep dermal and ful 4 2020-01-20
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Moderate-to-Sev… Ended

2022-502361-15-00 Moderate-to-Severe Plaque Psoriasis 5 2019-12-12
Corticosteroid in acute urticaria in emergency department Ended

2024-515308-38-00 Adults patients with isolated acute urticaria presentin 5 2019-09-21
A study to assess different investigational drugs for the treatment if hidradenitis suppurativa Ended

2023-509296-16-00 Moderate to severe hidradenitis suppurativa 4 2019-06-17